stanford university school of medicine
B cell receptor inhibitor causes chronic lymphocytic leukemia remission
A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the America…
Drugs warning — check the label
A new study highlights inconsistencies in black box warnings – medication-related safety warnings on a drug’s label – and argues for a more transparent and systematic approach to ensure these warnings are consistent across all drugs within a s…
RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
STANFORD, Calif. — Researchers at the Stanford University School of Medicine, in collaboration with BioParadox, Inc., have published data supporting the use of platelet-rich plasma as a promising biologic treatment for myocardial infarction (heart…
Evidence lacking for widespread use of costly antipsychotic drugs, says Stanford researcher
STANFORD, Calif. — Many prescriptions for the top-selling class of drugs, known as atypical antipsychotic medications, lack strong evidence that the drugs will actually help, a study by researchers at the Stanford University School of Medicine an…
Stanford-led study disproves link between genetic variant, risk of coronary artery disease
STANFORD, Calif. — A genetic marker touted as a predictor of coronary artery disease is no such thing, according to a study led by researchers at the Stanford University School of Medicine.
The massive international study, published online Oct….
Researcher studies newly discovered 'good' cholesterol gene
Researchers have found that a recently discovered gene regulates HDL (high density lipoproteins) cholesterol, also known as “good” cholesterol. The study, published in the February issue of the Journal of Clinical Investigation, could lead to new therapies for heart disease, said lead author Thomas Quertermous, MD. “This is a significant and unexpected finding, and the gene is going to be a real target for the prevention and treatment of heart disease,” said Quertermous, the William G. Irwin Professor and chief of cardiovascular medicine at Stanford University School of Medicine. “This type of thing doesn’t happen every day.”
Q&A on Stanford’s Stem Cell Research Announcement
The Stanford University School of Medicine announced on Dec. 10 plans to form an Institute for Cancer/Stem Cell Biology and Medicine. This multidisciplinary institute will study both stem cell biology and cancer biology, and will attempt to apply knowledge learned from stem cell biology to new treatments for cancer.
Q: Is Stanford planning on cloning human embryos?
A: No. The new institute will study adult stem cell lines generated from individuals with specific diseases such as cancer or neurodegenerative disorders. The institute will also investigate two different ways of generating new embryonic stem cell lines ? initially in mice. This may be extended to human cell lines if the techniques prove useful.
NASA to showcase innovative research for treating blindness
A technology designed to restore vision in patients suffering from age-related blindness will be demonstrated by a scientist at NASA Ames Research Center in California’s Silicon Valley today. Developed by NASA Ames in conjunction with the Stanford University School of Medicine, the “Vision Chip” may help improve age-related macular degeneration, the number one cause of blindness in the elderly. “Nanotechnology that could restore vision is an exciting example of how NASA science and engineering, origially intended for outer space, can return enormous dividends for everyday life here on Earth,” said Dr. David J. Loftus, a member of both the Life Sciences Division and the Integrated Product Team on Devices and Nanotechnology at NASA Ames.